In light of RxPonder results for postmenopausal women with early stage node positive HR+HER2- breast cancer, when is there a role for full axillary LN dissection to confirm degree of nodal involvement and when would sentinel LN evaluation be sufficient?
How would this affect adjuvant radiation plan in breast conservation therapy patients and mastectomy patients?
Answer from: Medical Oncologist at Community Practice
I don’t think the RxPonder study changes surgical management. Still follow Z0011 paradigm.
Comments
Medical Oncologist at Banner MD Anderson Cancer Center In RxPonder study, only 61% of patients had node d...
In RxPonder study, only 61% of patients had node d...